Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2023

Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2023

Graft Versus Host disease (GVHD) is an immune mediated systemic disorder associated with complex interaction between donor and recipient adaptive immunity. It is a common complication after hematopoietic stem cell transplant (HCT), here the graft recognizes the host as a foreign and attack the recipient's body cell. GvHD is of two types: acute GvHD which develops within 100 days of transplantation and chronic GvHD which develops after 100 days of transplantation.

GvHD occurs after the bone marrow transplants and stem cell transplants. Following are the other occurrences of GvHD allogenic bone transplantation, solid organs that are rich in lymphoid cells and un-irradiated blood.

Symptoms of GvHD range from mild to severe. Common acute symptoms include abdominal pain or cramps, nausea, vomiting, diarrhoea, jaundice, skin rash, itching, redness on areas of the skin and increased risk for infections. Chronic symptoms include dry eyes, burning sensation, fatigue, joint pains, shortness of breath, weight loss, etc.,

GvHD is diagnosed through imaging – X-ray abdomen, CT scan abdomen and chest, PET scan and MRI. Other diagnosis involves liver function tests, liver biopsy and capsule endoscopy.

Treatments depends on the severity of symptoms and organs involvement. Corticosteroids are commonly used treatment. Topical steroids are used to control local symptoms. Cyclosporine is added to the treatment regimen of chronic GvHD. Prophylactic treatment is recommended.

There are many other trials ongoing in GVHD Drug Development. These trials are studying a variety of new and existing drugs, as well as new ways to use existing drugs.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of Graft Versus Host Disease (GVHD) treatment such as Remestemcel-L, MaaT013, Vedolizumab, Axatilimab, and others. Key players involved in the development of therapies to treat Graft Versus Host Disease (GVHD) are Mesoblast Ltd, AstraZeneca, Takeda, Syndax Pharmaceuticals and others. One drug is under filing rejected stage, 9 drugs are under Phase III clinical trials and 30+ drugs are in Phase II clinical trials and some other drugs are under Phase I, phase 0, preclinical and discovery stages of development.

In Dec 2022, MaaT Pharma presented compelling clinical trial data of MaaT013 at the Annual Society of Hematology (ASH) Annual Meeting in New Orleans, US. In Dec 2022, Orca Bio presented interim data of Orca-Q Phase I clinical trial results at the 64th American Society of Haematology (ASH) annual meeting. In Nov 2022, Seres Therapeutics Inc reported third quarter 2022 financial results, in which the company mentioned that it has completed enrolment of SER-155 and expecting pre-planned review of safety data with DMSB before year end and reported the data in early 2023.

Report Highlights

Global Insight Service's, Graft Versus Host Disease (GVHD) - Drug Pipeline Landscape, 2023 report provides an overview of the Graft Versus Host Disease (GVHD) pipeline drugs. This report covers detailed insights on Graft Versus Host Disease (GVHD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Graft Versus Host Disease (GVHD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clincial trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.